Revolution Medicines Inc (RVMD) Stock Price, Quote & News

Company Profile

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 481 6801

Website: www.revmed.com

Address:

700 Saginaw Drive, Redwood City, United States

SnowLine Aug. 23 at 12:44 PM

$VSTM $RVMD what is the compelling case for either one or both?

1 · Reply

ChesterKaita Aug. 22 at 4:54 PM

$VSTM $RVMD has a market cap of $7 billion. just saying and they produced $0 revenue last year.. Our little Verastem is doing big things

0 · Reply

biolover Aug. 21 at 10:39 AM

$RVMD $VKTX I remember the drop. Don’t recall bad data. Similar situation. RVMD will be bigger than $MRK in oncology in the 2030s. Still undervalued at current prices but market cares about M&A short term. They made decision to GIA. No BO , no partnership. Signed financing deals in billions and will be dominant oncology force.

1 · Reply

EmSol Aug. 21 at 10:33 AM

$VKTX $RVMD did the same 2 years ago, after great date the stock drop from 35 to 15, and 1 year after was at $60. Be patient

0 · Reply

aaaccc Aug. 20 at 3:31 AM

$RVMD they are burning so much cash, and we still don't when will the phase 3 data be available. catalyst desert. huge share count. huge MC. price probably stay around where it is until they release phase 3 data.

0 · Reply

Randall99 Aug. 19 at 3:12 PM

$RVMD holding up well all things considered $XBI

0 · Reply

Randall99 Aug. 19 at 12:41 PM

$RVMD so many positive analyst ratings and notes. Bull pressure building. Really just need call sweeps to ignite this thing thru $40

0 · Reply

JarvisFlow Aug. 19 at 12:30 PM

Piper Sandler updates rating for Revolution Medicines ( $RVMD ) to Overweight, target set at 75.

0 · Reply

Randall99 Aug. 18 at 2:31 PM

$RVMD every single upmove just constantly faded. At what point will a pump materialize that holds and makes a little short scramble??

0 · Reply

EmSol Aug. 18 at 1:43 PM

$RUN $RVMD $80 look good for me

0 · Reply

Revolution Medicines, Inc. (RVMD) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:02 PM EDT - 17 days ago

Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress

Jul 30, 2025, 4:05 PM EDT - 24 days ago

Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025

Jul 24, 2025, 4:00 PM EDT - 4 weeks ago

Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor

Jul 23, 2025, 8:00 AM EDT - 4 weeks ago

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib

Jul 9, 2025, 8:00 AM EDT - 6 weeks ago

Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic's AI Discovery Tools to Pursue New Drug Candidates

Jun 30, 2025, 8:00 AM EDT - 7 weeks ago

Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors

Jun 30, 2025, 8:00 AM EDT - 7 weeks ago

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

SMMT

Jun 24, 2025, 7:19 AM EDT - 2 months ago

Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug

RPRX

Jun 24, 2025, 7:00 AM EDT - 2 months ago

Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers

Jun 23, 2025, 9:00 AM EDT - 2 months ago

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations

Jun 19, 2025, 11:54 AM EDT - 2 months ago

Revolution Medicines: Positioning Itself To Capture One Of The Largest Cancer Targets In History

May 14, 2025, 8:00 AM EDT - 3 months ago

Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer

May 7, 2025, 6:58 PM EDT - 3 months ago

Revolution Medicines, Inc. (RVMD) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:02 PM EDT - 3 months ago

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

Apr 30, 2025, 4:05 PM EDT - 4 months ago

Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025

Apr 28, 2025, 11:02 AM EDT - 4 months ago

Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?

Apr 27, 2025, 12:05 PM EDT - 4 months ago

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

Apr 1, 2025, 4:05 PM EDT - 5 months ago

Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 31, 2025, 4:05 PM EDT - 5 months ago

Revolution Medicines to Participate in April 2025 Investor Conferences

Feb 27, 2025, 9:05 AM EST - 6 months ago

Revolution Medicines, Inc. (RVMD) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:02 PM EST - 6 months ago

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

Feb 24, 2025, 4:05 PM EST - 6 months ago

Revolution Medicines to Participate in March 2025 Investor Conferences

Feb 19, 2025, 4:05 PM EST - 6 months ago

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

Jan 29, 2025, 4:05 PM EST - 7 months ago

Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Jan 6, 2025, 4:05 PM EST - 8 months ago

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 5, 2024, 4:05 PM EST - 9 months ago

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 4, 2024, 9:09 AM EST - 9 months ago

Revolution Medicines: Risky Buy On Recent Share Price Dip

Dec 4, 2024, 6:15 AM EST - 9 months ago

Top 3 Health Care Stocks That Could Blast Off In December

ELAN SHC

Dec 3, 2024, 10:38 PM EST - 9 months ago

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Dec 2, 2024, 4:31 PM EST - 9 months ago

Revolution Medicines Announces Commencement of Public Offering of Common Stock

Dec 2, 2024, 7:30 AM EST - 9 months ago

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

Nov 27, 2024, 4:05 PM EST - 9 months ago

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

Nov 6, 2024, 7:52 PM EST - 10 months ago

Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:02 PM EST - 10 months ago

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

Nov 5, 2024, 9:00 AM EST - 10 months ago

Revolution Medicines to Participate in Upcoming Investor Conferences

Oct 30, 2024, 4:05 PM EDT - 10 months ago

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

Oct 25, 2024, 4:15 AM EDT - 10 months ago

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Oct 23, 2024, 6:00 AM EDT - 10 months ago

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Oct 21, 2024, 4:05 PM EDT - 10 months ago

Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Oct 7, 2024, 9:00 AM EDT - 11 months ago

Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast

Aug 11, 2024, 2:00 AM EDT - 1 year ago

Revolution Medicines, Inc. (RVMD) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024

Jul 16, 2024, 8:16 AM EDT - 1 year ago

Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter

AVAH FULC

$Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer$

Jul 11, 2024, 12:00 PM EDT - 1 year ago

Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer

Jul 8, 2024, 4:05 PM EDT - 1 year ago

Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024

Jun 5, 2024, 4:05 PM EDT - 1 year ago

Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

May 8, 2024, 4:02 PM EDT - 1 year ago

Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress

SnowLine Aug. 23 at 12:44 PM

$VSTM $RVMD what is the compelling case for either one or both?

1 · Reply

ChesterKaita Aug. 22 at 4:54 PM

$VSTM $RVMD has a market cap of $7 billion. just saying and they produced $0 revenue last year.. Our little Verastem is doing big things

0 · Reply

biolover Aug. 21 at 10:39 AM

1 · Reply

EmSol Aug. 21 at 10:33 AM

$VKTX $RVMD did the same 2 years ago, after great date the stock drop from 35 to 15, and 1 year after was at $60. Be patient

0 · Reply

aaaccc Aug. 20 at 3:31 AM

0 · Reply

Randall99 Aug. 19 at 3:12 PM

$RVMD holding up well all things considered $XBI

0 · Reply

Randall99 Aug. 19 at 12:41 PM

$RVMD so many positive analyst ratings and notes. Bull pressure building. Really just need call sweeps to ignite this thing thru $40

0 · Reply

JarvisFlow Aug. 19 at 12:30 PM

Piper Sandler updates rating for Revolution Medicines ( $RVMD ) to Overweight, target set at 75.

0 · Reply

Randall99 Aug. 18 at 2:31 PM

$RVMD every single upmove just constantly faded. At what point will a pump materialize that holds and makes a little short scramble??

0 · Reply

EmSol Aug. 18 at 1:43 PM

$RUN $RVMD $80 look good for me

0 · Reply

JarvisFlow Aug. 18 at 1:00 PM

LifeSci Capital has updated their rating for Revolution Medicines ( $RVMD ) to Outperform with a price target of 80.

0 · Reply

EmSol Aug. 18 at 11:32 AM

$RUN happy Sunny Monday for a run. I had 80 k profit in 1 months, I decided to sale all my shares, except my 80k profit, if it goes at $36 I will have 240k in my pocket and if it goes to 0, I will not loss anything but don’t worry, see you at $36. It was just good time to sale and move on with new position like $RVMD

0 · Reply

biolover Aug. 17 at 11:40 PM

$TNGX 462 combo with $RVMD will be game changer in pancreatic cancer to start ( later in others such as lung cancer). Two different mechanisms, no overlap I. toxicity. RVMD drug in second line pancreatic is doing better than chemo in front line. Two drugs together could drive major and durable benefit to needy pts and shareholders. Will likely be moved quickly to front line. Big population and durability in response could drive big value

1 · Reply

EmSol Aug. 17 at 2:46 PM

$RVMD its time to be back, the next two year will be glorious

0 · Reply

Randall99 Aug. 15 at 1:42 PM

$RVMD 36.50 is the technical line in the sand. Now needs to reclaim 20 and 50d sma. Decent volume recently as well. Only thing still missing is consistent call volume to really spark the shorts. Institutionally and insider held so they aren’t budging. Just need shorts a reason to start spraying

0 · Reply

topstockalerts Aug. 15 at 12:03 PM

$RVMD heating up…

0 · Reply

Thestocktraderhubzee Aug. 15 at 11:01 AM

$RVMD Wells Fargo Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Target of $67

0 · Reply

JarvisFlow Aug. 15 at 11:00 AM

Wells Fargo updates rating for Revolution Medicines ( $RVMD ) to Overweight, target set at 67.

0 · Reply

outlawinvestor1 Aug. 14 at 2:13 PM

$VSTM added. fda approved product + G12D inhibitor - very undervalued imho. $RVMD $ARVN $ERAS $ELTX

1 · Reply

Irish_lass Aug. 13 at 7:24 PM

$RVMD World Lung Abstract

0 · Reply

biolover Aug. 10 at 11:28 PM

$LLY $NVO $PFE $VKTX Viking CEO alluded to “Very high interest with hundreds of investigators participating in recent investigator meeting.” These are high volume obesity centers ( 105 participating in USA ) and almost all sites up and running now as “ they don't want to miss chance to enroll patients” Viking should probably do more offerings / loans in the next 2 years ( like $RVMD doing ) and move the program on its own. Drug popularity is already there with busy USA obesity centers and I don’t believe Viking needs Pfizer or any other one

1 · Reply

VIX_Bandit Aug. 7 at 6:47 AM

$RVMD Small-cap biotech volatile but trending. Breakout above $25 could spark short squeeze (30% short interest).

1 · Reply

Market Cap	6.92B
Revenue (ttm)	0.00
Net Income (ttm)	-600.09M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.13

Volume	1,091,700
Avg Vol	2,369,692
Day's Range	N/A - N/A
Shares Out	186.93M
Stochastic %K	76%
Beta	1.16
Analysts	Strong Sell
Price Target	$72.40